Geron | GERN - Des Atouts





Des Atouts Changement Date
Amgen USD 92.5B 1.92B 2026-03
Bio Techne USD 2.55B 27.9M 2026-03
Cassava Sciences USD 108.37M 9.99M 2026-03
Cytokinetics USD 1.27B 151.06M 2026-03
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Exelixis USD 2.59B 250.83M 2026-03
Genmab DKK 12.87B 5.85B 2025-12
Geron USD 534.12M 36.42M 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
Incyte USD 7.34B 381.14M 2026-03
MacroGenics USD 217.87M 38.97M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Novavax USD 1.04B 133.35M 2026-03